尽管分析师下调了盈利预测，但百时美施贵宝 （Bristol-Myers Squibb） 仍看到大量投资买入。 Bristol-Myers Squibb sees major investment buys despite analysts lowering earnings forecasts.

Bristol-Myers Squibb是一家大型生物制药公司,在2024年第四季度,有两个投资集团NFJ Investments和Finward Bancorp购买了大量股份。 Bristol-Myers Squibb, a major biopharmaceutical firm, saw two investment groups, NFJ Investment and Finward Bancorp, purchase significant shares in the fourth quarter of 2024. 公司报告强的收益, 超过分析师的预期, 市值为1017亿美元. The company reported strong earnings, beating analysts' expectations, and has a market cap of $101.70 billion. William Blair的分析师最近降低了 EPS对该公司的估算。 Analysts at William Blair recently lowered their EPS estimates for the company. Bristol-Myers Squibb提供各种疾病产品,包括Eliquis和Opdivo等著名药物。 Bristol-Myers Squibb offers products for various diseases, including notable drugs like Eliquis and Opdivo.